Scarica l'app Stockscreener
33.58
6.03%
1.91
Dopo l'orario di chiusura:
33.58
Precedente Chiudi:
$31.67
Aprire:
$30.74
Volume 24 ore:
218.32K
Relative Volume:
0.65
Capitalizzazione di mercato:
$1.60B
Reddito:
-
Utile/perdita netta:
$-111.48M
Rapporto P/E:
-11.72
EPS:
-2.865
Flusso di cassa netto:
$-88.09M
1 W Prestazione:
+15.79%
1M Prestazione:
+18.36%
6M Prestazione:
+17.66%
1 anno Prestazione:
+237.15%
Intervallo 1D:
$30.74
$34.00
Intervallo di 1 settimana:
$27.02
$34.00
Portata 52W:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
33.58 | 1.60B | 0 | -111.48M | -88.09M | -2.865 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Wells Fargo | Overweight |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-09-16 | Iniziato | Truist | Buy |
| 2025-08-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Mostra tutto
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
(RAPP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform? - simplywall.st
Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting - Sahm
Rapport Therapeutics to present epilepsy trial data at AAN By Investing.com - Investing.com Australia
Rapport Therapeutics to present epilepsy trial data at AAN - Investing.com
Rapport's new 8-week seizure data heads to a major neurology meeting - Stock Titan
Market Catalysts: Is Rapport Therapeutics Inc a good stock for dollar cost averaging2026 Growth vs Value & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Rapport Therapeutics COO Gault sells $281k in stock By Investing.com - Investing.com South Africa
Rapport Therapeutics COO Gault sells $281k in stock - Investing.com
Rapport Therapeutics Insider Sold Shares Worth $281,857, According to a Recent SEC Filing - MarketScreener
Rapport Therapeutics (RAPP) COO sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
10,000-share Rule 144 sale by RAPP (NASDAQ: RAPP) lists $278,400 value - Stock Titan
Patterns Watch: What is the cash position of Rapport Therapeutics IncMarket Sentiment Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Aug Ideas: What hedge funds are buying Rapport Therapeutics Inc2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Will Rapport Therapeutics Inc benefit from AI trendsPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Will Rapport Therapeutics' RAP-219 Deliver A Pipeline-in-a-Product Story? - RTTNews
Rapport Therapeutics (NASDAQ:RAPP) Raised to “Strong-Buy” at Truist Financial - defenseworld.net
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k By Investing.com - Investing.com South Africa
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k - Investing.com
Rapport Therapeutics Insider Sold Shares Worth $303,355, According to a Recent SEC Filing - MarketScreener
Rapport Therapeutics (RAPP) CDO sells 10,115 shares under 10b5-1 plan - Stock Titan
All Essential Information Regarding Rapport Therapeutics, Inc. (RAPP) Rating Raised to Buy - Bitget
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Upgraded at Truist Financial - MarketBeat
RAPP (NASDAQ: RAPP) insider sale reported: 2,840 common shares - Stock Titan
Geopolitics Watch: Will Rapport Therapeutics Inc stock go up in YEAR2026 Price Targets & AI Driven Price Predictions - baoquankhu1.vn
(RAPP) Risk Channels and Responsive Allocation - Stock Traders Daily
RAPP SEC FilingsRapport Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RAPP Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Aug Selloffs: Why is Rapport Therapeutics Inc stock going up2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Buyout Rumor: Does Rapport Therapeutics Inc have strong fundamentals2026 Highlights & Long-Term Capital Growth Strategies - baoquankhu1.vn
Sell Signal: Will Rapport Therapeutics Inc benefit from AI trends2026 Drop Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Update Recap: Why is Rapport Therapeutics Inc stock going up2026 Volume Leaders & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Whats the outlook for Rapport Therapeutics Incs sectorWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Take Profit: Is Rapport Therapeutics Inc undervalued by DCF analysisWeekly Loss Report & Stock Portfolio Risk Management - baoquankhu1.vn
Truist reiterates Rapport Therapeutics stock rating on phase 3 plans By Investing.com - ca.investing.com
Truist reiterates Rapport Therapeutics stock rating on phase 3 plans - Investing.com
Baker BROS. Advisors LP Has $45.95 Million Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
HC Wainwright & Co. Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - msn.com
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Why Rapport Therapeutics (RAPP) Is Down 7.9% After RAP-219 China Deal And Shelf Filing - simplywall.st
Q1 EPS Forecast for Rapport Therapeutics Boosted by Analyst - Defense World
Q1 EPS Estimate for Rapport Therapeutics Lifted by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
(RAPP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $50.80 Consensus PT from Brokerages - Defense World
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):